The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse acoramidis (Beyonttra®) from the basic healthcare package. This medicine can be used in certain patients with variants of amyloidosis and cardiomyopathy. Amyloidosis is a disease in which the body does not handle a certain type of protein well. If the minister adopts our advice, acoramidis will be included in the Medicine Reimbursement System (GVS). Only then will this medicinal product be reimbursed from the healthcare insurer's basic healthcare package. We do recommend additional conditions for reimbursement.
Current state of affairs: advisory report sent to the Minister
The National Health Care Institute has sent this advice to the Minister of VWS. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic healthcare package.
Acoramidis is intended for certain people with amyloidosis and cardiomyopathy
Acoramidis is the active substance. The brand name is Beyonttra®. The medicinal product is a tablet that is taken daily.
The medicine can be used in adults with variants of amyloidosis with cardiomyopathy (ATTR-CM). Cardiomyopathy is a heart muscle disease. Amyloidosis is a collective term for diseases in which the body fails to process a specific type of protein effectively. In healthy people, the body’s own proteins are folded so they can do their job. In people with amyloidosis, the folding of these proteins goes wrong. These proteins clot in places in the body where they do not belong. They also lose their function, causing damage to tissues and organs.
In people with ATTR-CM, these proteins accumulate mainly in the heart. This interferes with the tissue structure and function of the heart. This leads to thickening and stiffness of the heart muscle, and eventually to cardiomyopathy and heart failure.
National Health Care Institute advice on the reimbursement of acoramidis (Beyonttra®)
The National Health Care Institute advises the Minister of VWS to reimburse acoramidis (Beyonttra®) from the basic healthcare package. The recommendation is to include the medicinal product in List 1A of the GVS. Certain additional conditions, the so-called List 2 conditions, apply for acoramidis (Beyonttra®).
For more information on the GVS and the Lists 1A, 1B and 2, see page 'Reimbursement of outpatient medicines'.
Conditions for reimbursement of acoramidis (Beyonttra®)
Only for insured patients aged 18 and older with wild-type or hereditary transthyretin amyloidosis with cardiomyopathy and NYHA class I-II.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Minister of VWS asks the National Health Care Institute to make an assessment. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic healthcare package.
Explanation about the reimbursement of medicinal products
Acoramidis is an extramural medicinal product. Extramural means: medicines for home use that can be obtained at the pharmacy with the prescription from a physician. They are only reimbursed from the basic healthcare package if they are listed in the GVS.